New horizons for focused ultrasound (FUS) – therapeutic applications in neurodegenerative diseases

Cacabelos, 2016, Novel therapeutic strategies for dementia, CNS Neurol Disord Drug Targets, 15, 141, 10.2174/1871527315666160202121548 Miller, 2015, Biomarkers of Parkinson's disease (PD): present and future, Metabolism, 64, S40, 10.1016/j.metabol.2014.10.030 Chen, 2014, A new brain drug delivery strategy: focused ultrasound-enhanced intranasal drug delivery, PLoS One, 9, e108880, 10.1371/journal.pone.0108880 Aryal, 2014, Ultrasound-mediated blood–brain barrier disruption for targeted drug delivery in the central nervous system, Adv Drug Deliv Rev, 72, 94, 10.1016/j.addr.2014.01.008 Ghanouni, 2015, Transcranial MR-guided focused ultrasound: a review of the technology and neuro applications, AJR Am J Roentgenol, 205, 150, 10.2214/AJR.14.13632 Piper, 2016, Focused ultrasound as a non-invasive intervention for neurological disease: a review, Br J Neurosurg, 30, 286, 10.3109/02688697.2016.1173189 Leinenga, 2016, Ultrasound treatment of neurological diseases – current and emerging applications, Nat Rev Neurol, 12, 161, 10.1038/nrneurol.2016.13 ter Haar, 2007, Therapeutic applications of ultrasound, Prog Biophys Mol Biol, 93, 111, 10.1016/j.pbiomolbio.2006.07.005 Sirsi, 2009, Microbubble compositions, properties and biomedical applications, Bubble Sci Eng Technol, 1, 3, 10.1179/175889709X446507 McDannold, 2012, Temporary disruption of the blood–brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques, Cancer Res, 72, 3653, 10.1158/0008-5472.CAN-12-0128 Herrup, 2015, The case for rejecting the amyloid cascae hypothesis, Nat Neurosci, 18, 794, 10.1038/nn.4017 Toyn, 2015, What lessons can be learned from failed Alzheimer's disease trials?, Expert Rev Clin Pharmacol, 8, 267, 10.1586/17512433.2015.1034690 Selkoe, 2016, The amyloid hypothesis of Alzheimer's disease at 25years, EMBO Mol Med, 10.15252/emmm.201606210 George, 2015, Immunotherapy in Parkinson's disease: micromanaging alpha-synuclein aggregation, J Parkinsons Dis, 5, 413, 10.3233/JPD-150630 Jordão, 2010, Antibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-beta plaque load in the TgCRND8 mouse model of Alzheimer's disease, PLoS One, 5, e10549, 10.1371/journal.pone.0010549 Jordão, 2013, Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound, Exp Neurol, 248, 16, 10.1016/j.expneurol.2013.05.008 Burgess, 2014, Alzheimer disease in a mouse model: MR imaging-guided focused ultrasound targeted to the hippocampus opens the blood–brain barrier and improves pathologic abnormalities and behavior, Radiology, 273, 736, 10.1148/radiol.14140245 Leinenga, 2015, Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer's disease mouse model, Sci Transl Med, 7, 278ra33, 10.1126/scitranslmed.aaa2512 Prajapati, 2011, Current perspectives on potential role of albumin in neuroprotection, Rev Neurosci, 22, 355, 10.1515/rns.2011.028 Ranaivo, 2010, Albumin activates astrocytes and microglia through mitogen-activated protein kinase pathways, Brain Res, 1313C, 222, 10.1016/j.brainres.2009.11.063 Ezra, 2016, Multifunctional effect of human serum albumin reduces Alzheimer's disease related pathologies in the 3xTg mouse model, J Alzheimers Dis, 50, 175, 10.3233/JAD-150694 Boada, 2009, Amyloid-targeted therapeutics in Alzheimer's disease: use of human albumin in plasma exchange as a novel approach for Aβ mobilization, Drug News Perspect, 22, 325, 10.1358/dnp.2009.22.6.1395256 Lindstrom, 2014, Immunotherapy targeting A-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders, Immunotherapy, 6, 141, 10.2217/imt.13.162 Cummins, 2012, What is the most promising treatment for Parkinson's disease: genes, cells, growth factors or none of the above?, Regen Med, 7, 617, 10.2217/rme.12.47 Kelly, 2015, Viral vector delivery of neurotrophic factors for Parkinson's disease therapy, Expert Rev Mol Med, 17, 1, 10.1017/erm.2015.6 Samiotaki, 2015, Enhanced delivery and bioactivity of the neurturin neurotrophic factor through focused ultrasound-mediated blood–brain barrier opening in vivo, J Cereb Blood Flow Metab, 35, 611, 10.1038/jcbfm.2014.236 Scarcelli, 2014, Stimulation of hippocampal neurogenesis by transcranial focused ultrasound and microbubbles in adult mice, Brain Stimul, 7, 304, 10.1016/j.brs.2013.12.012 Yoo, 2011, Focused ultrasound modulates region-specific brain activity, Neuroimage, 56, 1267, 10.1016/j.neuroimage.2011.02.058 Downs, 2015, Long-term safety of repeated blood–brain barrier opening via focused ultrasound with microbubbles in non-human primates performing a cognitive task, PLoS One, 10, e0125911, 10.1371/journal.pone.0125911 Burgess, 2015, Focused ultrasound-mediated drug delivery through the blood–brain barrier, Expert Rev Neurother, 15, 477, 10.1586/14737175.2015.1028369 Samiotaki, 2013, Dependence of the reversibility of focused-ultrasound-induced blood–brain barrier opening on pressure and pulse length In Vivo, IEEE Trans Ultrason Ferroelectr Freq Control, 60, 2257, 10.1109/TUFFC.2013.6644731 ter Haar, 2009, Safety and bio-effects of ultrasound contrast agents, Med Biol Eng Comput, 47, 893, 10.1007/s11517-009-0507-3 Xie, 2008, Effects of transcranial ultrasound and intravenous microbubbles on blood brain barrier permeability in a large animal model, Ultrasound Med Biol, 34, 2028, 10.1016/j.ultrasmedbio.2008.05.004